

16 Jan 2018 | News

QUOTED. Jan. 16, 2018. Kelly Londy.

by

Check out what Lumicell CEO Kelly Londy had to say about why the device-maker is developing its *LUM* system to treat prostate, colorectal, esophageal and pancreatic cancers.

"We think [the *LUM* system] will have wide ability to detect a variety of cancers because of the activation mode of [the firm's *LUM015* cathepsin-activatable fluorescent optical contrast agent]. Unlike chemotherapy, which attacks all the cells, ours is different in that it's a protease, so the cancer cells reach out and grab it and pull it in, and when it does that the molecule cleaves and fluoresces. So only the cells around the tumor glow, not all the cells." –Kelly Londy, CEO, Lumicell

> Find out more: [San Antonio Breast Cancer Symposium: New Diagnostics From Myriad, Lumicell, Agendia](#)

[Click here](#) for a free trial of *Medtech Insight*